IO Biotech and Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 With KEYTRUDA® (pembrolizumab) in a Ph 2 Trial in Patients with Resectable Tumors

“We are pleased to extend our collaboration with Merck into this new exploration of IO102-IO103 in combination with pembrolizumab in earlier, neoadjuvant and adjuvant settings,” said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech. “IO102-IO103 has shown promising early clinical activity with a positive safety profile in melanoma thus far and, as highlighted in our Key Opinion Leader webinar this past spring, a compelling need remains among patients with advanced melanoma for effective treatments with reduced toxicity. We believe that the novel biology of IO102-IO103 represents a potential paradigm shift in the management of additional cancer types beyond melanoma, and we look forward to expanding our dataset to evaluate our medicine in combination with pembrolizumab in earlier neoadjuvant and adjuvant settings.”

Share:

More News

“The eNRGy study highlights that NRG1 fusions are an actionable therapeutic target and the importance of developing biomarker-driven therapies like zenocutuzumab,” said Debasish Roychowdhury, MD, Chief Technology Officer at Partner Therapeutics. “We are deeply grateful to the Merus team that designed, researched and developed zenocutuzumab, the eNRGy trial investigators, and

Pnina Fishman, CSO & Chairperson of Can-Fite BioPharma, commented: “We are pleased to offer this compassionate use program with Namodenoson for eligible patient in the US to address the unmet medical needs for pancreatic cancer. Initiating this program is another milestone achieved for Namodenoson, and concurrently to our ongoing Phase

“We are deeply disappointed by these results from our Phase 1 trial. Despite continuing to demonstrate differentiated safety as a more combinable ADC, updated efficacy data suggest that treatment with EO-3021 does not meet our bar for success and is insufficient to provide patients a competitive benefit-risk profile compared to

Søren Bregenholt, CEO of Alligator, commented: “The FDA’s recognition of HLX22/AC101’s potential with Orphan Drug Designation is a notable recognition. While Alligator’s is not directly involved in the development of HLX22/AC101, we continue to follow its progress as it potentially represents future income to Alligator.”